grants_govPA-27-101
Open
NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)
- Response deadline
- Apr 5, 2029 Due in 901 days
- Date posted
- May 28, 2026
- Source
- Open notice
Description
The NIH Phase IIB Strategic Breakthrough award bridges the funding gap between the end of a Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase II award and commercialization. The Phase IIB Strategic Breakthrough provides previously funded NIH SBIR or STTR projects additional support for later-stage research and development (R&D).
Classifications
- NAICS93.853
Documents (1)
- DownloadPA-27-101-Revised-Full-Announcement.htmltext/html;charset=UTF-8170 KB
Contacts
- seedinfo@nih.gov301-402-2541
Similar contracts
- Mechanistic Evaluation of Therapeutic Targets derived from Treatable Traits to Improve CNS Outcomes in People with HIV (R21/R33 Clinical Trial Not Allowed)Due Oct 28, 2027
- NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01 Clinical Trial Not Allowed)Due Apr 17, 2029
- NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)Due Mar 9, 2029
- Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed)Due Sep 28, 2026
- NINDS Child Neurology Career Development Program (CNCDP) (K12 - Clinical Trial Not Allowed)Due Jul 10, 2026
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)Due Nov 10, 2026